List of abbreviations: 1,5-AG, 1,5-anhydroglucitol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; CPR, C-peptide reactivity; DBP, diastolic blood Original ©The Japan Endocrine Society pressure; GA, glycoalbumin; GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IRG, immunoreactive glucagons; JDS, Japanese standard measurement method; LDL-C, low-density lipoprotein cholesterol; MTT, meal tolerance tests; NGSP, National Glycohemoglobin Standardization Program; SBP, systolic blood pressure; SMBG, self-monitoring of blood glucose; TC, total cholesterol; TG, triglyceride; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus study, fulfilled all of the following inclusion criteria: 1. Patients had to be 20-80 years of age, should have had T1DM for at least 6 months, and should have been treated with intensive insulin therapy (i.e., at least 4 insulin injections per day). 2. The ad lib CPR measured before the study was <0.5 ng/mL. 3. All patients had an HbA1c level of 6.4-8.9% (NGSP), and a BMI of <30 kg/m 2 at week 0. The exclusion criteria were any major illness or endocrinological, cardiac, renal, gastrointestinal or severe hepatic disorder, and severe neuropathy (associated with autonomic neuropathy) or severe retinopathy (preproliferative retinopathy or more severe stages); in addition, pregnant or lactating females, and females not using adequate contraception were excluded. The characteristics of the subjects are shown in Table 1 . The study protocol was approved by the Ethics Committee of Hyogo College of Medicine, and written informed consent was provided in accordance with the ethical principles stated in the Declaration of Helsinki. lin therapy, is the current strategy of choice for treatment of T1DM, it is still difficult to minimize daily fluctuations of blood glucose levels.
Since about half of the daily endogenous insulin is released in response to the consumption of meals, and the remaining half is basally secreted, 50% of the daily insulin should be given as a basal supplement and the other 50% should be administered preprandially in T1DM patients having a westernized life style [4] . However, about 30-40% of daily insulin is usually given as a basal supplement and the other 60-70% is given preprandially to Japanese T1DM patients [5] . The difference of the ratio of basal/bolus insulin supplementation between T1DM in Japan and westernized countries might be dependent on the difference of whole body insulin resistance and hepatic insulin resistance between T1DM in Japan and westernized countries. The difference of the percentage of carbohydrate intake at each meal might also affect on the difference of the ratio of basal/bolus insulin supplementation as well.
Miglitol, an α-glucosidase inhibitor, has been primarily used in patients with T2DM for establishing better glycemic control by preventing postprandial hyperglycemia via inhibition of digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides, particularly in the upper small intestine. After oral administration, miglitol is rapidly and completely absorbed in the upper small intestine, but other types of α-glucosidase inhibitors are poorly absorbed there [6] . In T2DM patients treated with insulin therapy, combination therapy of insulin and miglitol was effective for regulating postprandial glucose and improving glycemic control [7] .
In this study, we added miglitol on intensive insulin therapy in T1DM patients and investigated the efficacy of miglitol by examining blood glucose levels, daily insulin doses, body weight changes, and frequency of hypoglycemia. In addition, we analyzed changes in incretin hormone responses by addition of miglitol on intensive insulin therapy in T1DM patients during MTT.
Subjects and Methods

Subjects
We recruited 11 outpatients with T1DM who had been regularly attending our Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine. Each participant, who had provided written informed consent before the start of the 0 Data are means ± SD. Eight subjects had GAD-antibodies, and the rest 3 subjects were diagnosed as T1DM due to their clinical features with acute onset. Five subjects had mild neuropathy; Achilles tendon reflexes were only slightly decreased. T1DM, type 1 diabetes mellitus; BMI indicates body mass index; NGSP, National Glycohemoglobin Standardization Program; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, lowdensity lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; SDR, simple diabetic retinopathy meal, and at bedtime), at least once a week. All SMBG data, as well as all occurrences of hypoglycemia, when they became aware of symptoms of hypoglycemia or when blood glucose levels fell below 60 mg/dL were self-recorded in a diary. In addition, a questionnaire regarding appetite, nausea, abdominal bloating, and diarrhea was administered during medical interviews at weeks 0, 4, 8, and 12.
Meal tolerance test (MTT)
Of the 11 patients, 9 who agreed to participate in MTT were instructed to take test meals (JANEF E460F18 ® Kewpie Corporation, Tokyo, Japan, 460 kcal 56.5 g carbohydrate, 18 g protein, and 18 g fat) in the overnight fasting state as breakfast for MTT at week 0 and 12. At week 12, patients were instructed to take 50 mg of miglitol immediately before starting the test. For active GLP-1 and total GIP analyses, catheters were placed in cubital veins and blood samples were withdrawn directly into EDTA-2Na coated blood collection tubes (1.25 mg/mL blood) containing aprotinin and an inhibitor of DPP-4 (10 μL/mL of blood; Linco Research Inc., MO, USA) before the start of MTT and 30, 60 and 120 min after ingestion. The levels of plasma glucose, IRG, total GIP, and active GLP-1 were measured in each sample. Plasma glucose concentrations were measured immediately by the glucose oxidase method. Plasma levels of glucagon were measured by the radioimmunoassay method, using the Glucagon kit Daiichi-II (TFB Corp., CA, USA) at Cosmic Corp. (Tokyo, Japan). Plasma levels of active GLP-1 were measured by the ELISA method, using the GLP-1 Active ELISA kit (Millipore Corp., MA, USA)
Study design and methods
As shown in Fig. 1 , this study consisted of a 4-to 8-week observation period and a 12-week treatment period. From week 0 to 4 of the treatment period, enrolled subjects were instructed to take a 25 mg miglitol tablet immediately before meals 3 times daily. From week 4 to 12, they were instructed to take a 50 mg miglitol tablet immediately before meals 3 times daily. Throughout the observation and treatment periods, patients were instructed to follow the same diet and exercise regimen as they did before the study. Changes in the type of insulin or drugs were prohibited; however, the dosage of insulin could be adjusted to achieve target blood glucose (; preprandial; 70 -120 mg/dl, 2hr postprandial; 120 -160 mg/dl). Ad-lib C-peptide was measured by lumipulse presto C-peptide (Fujirebio Inc, Tokyo, Japan). The levels of HbA1c, GA, 1,5-AG, body weight, AST, ALT and blood pressure (SBP and DBP) were measured at weeks 0, 4, 8, and 12. The levels of LDL-C, HDL-C, TG and TC were measured in fasting state at weeks 0 and 12. The HbA1c value (%) in the present study is shown as the NGSP equivalent value (%) calculated on the basis of the following formula [8] : HbA1c (NGSP) (%) = HbA1c (JDS) (%) + 0.4 (%). All levels of HbA1c in this study are expressed as NGSP equivalent values. The urinary albumin excretion rate was measured at weeks 0 and 12. Throughout the study period, measurements of blood glucose levels were performed through SMBG before each meal 3 times a day, and 1 or 2 h after each meal, i.e., 6 measurements per day to titrate the insulin regimen. All subjects were additionally instructed to perform SMBG 10 times daily (before every meal, 1 and 2 h after every 
results
HbA1c, GA, and 1,5-AG levels
Serial changes in parameters from week 0 to 12 are shown in Table 2 . The mean HbA1c level before treatment was 7.4%, and it decreased significantly to 7.0% at week 4 (p = 0.011), 7.0% at week 8 (p = 0.013), and 6.9% at week 12 (p = 0.0099). The GA level decreased significantly from 23.6% at week 0 to 21.7% at week 12 (p = 0.0208). The level of 1,5-AG was significantly improved from 5.3 μg/mL at week 0 to 8.0 μg/mL at week 4 (p = 0.021) and 8.1 μg/mL at week 12 (p = 0.013).
BMI and hypoglycemic events
The BMI decreased significantly from 20.8 kg/m 2 at week 0 to 20.4 kg/m 2 at week 4 (p = 0.0077), 20.5 kg/ m 2 at week 8 (p = 0.0093), and to 20.4 kg/m 2 at week 12 (p = 0.0051). The frequency of weekly hypoglyce-at Cosmic Corp. (Tokyo, Japan) according to the manufacturer's instruction. Plasma levels of total GIP were also measured by the ELISA method, using the Human GIP (total) ELISA kit (Millipore Corp.) at Cosmic Corp. (Tokyo, Japan). The study was performed from March 2009 to March 2010.
Statistical analysis
The results of statistical analysis are shown as the mean ± standard deviation (SD) unless otherwise specified. Analyses of efficacy were carried out at each timepoint with Wilcoxon signed rank test against the baseline. Comparisons of time curves during the MTT were analyzed by two-way repeated measures ANOVA, followed by Wilcoxon singned rank test at each time measurement value. A P value of less than 0.05 was considered to indicate statistically significant differences. Data are expressed as mean±SD. Changes in parameters for blood glucose control from Week 0 to 12. HbA1c: hemoglobin A1c; GA: glycoalbumin; 1,5-AG: 1,5-anhydroglucitol; BMI: Body mass index; NGSP, National Glycohemoglobin Standardization Program; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; AST,aspartate aminotransferase; ALT, alanine aminotransferase; N.S., not significant 2. Compared to week 0, at week 12 the blood glucose levels after meals tended to be lower and the blood glucose level 1 h after dinner was significantly lower (p = 0.008).
Results of the questionnaire survey
No substantial change was found in appetite, nausea, bloating sensation in the abdomen, constipation, and diarrhea in weeks 0, 4, 8, and 12.
Plasma glucose and incretin levels in MTT at weeks 0 and 12
The changes in plasma glucose, active GLP-1, total GIP and IRG during MTT from week 0 to 12 are shown in Figs. 3A-D. While the mean plasma glucose levels at 0 min at weeks 0 and 12 were almost similar, those at 60, and 120 min were significantly decreased from 251.9 mg/dL to 133.0 mg/dL (p = 0.0077) and from 231.3 mg/dL to 149.9 mg/dL (p = 0.021), respectively (Fig. 3A) . Fig. 3B demonstrates that the change in active GLP-1 at 120 min at week 12 significantly increased from 1.9 pmol/L to 6.8 pmol/L (p = 0.015). The change in total GIP at week 12 significantly decreased from 587.7 pg/mL to 233.2 pg/mL (p = 0.011) at 30 min, from 551.8 pg/mL to 189.6 pg/mL (p = 0.0077) at 60 min, and from 251.4 pg/mL to 128.2 pg/mL (p = 0.038) at 120 min (Fig. 3C ). However, there was no significant difference of the change in IRG between weeks 0 and 12 (Fig. 3D ). mic events before lunch and dinner markedly and significantly decreased from 1.0 at week 0 to 0.3 at week 12 (p = 0.012).
Dosage of insulin (total, basal, and bolus)
The mean total daily insulin dosage decreased from 36.2 units at week 0 to 35.6 units at week 4 (p = 0.028), 33.9 units at week 8 (p = 0.012), and to 33.8 units at week 12 (p = 0.012). While the daily basal insulin dosage was not changed, the daily bolus insulin dosage decreased from 24.2 units at week 0, to 23.8 units at week 4 (p = 0.043), 22.3 units at week 8 (p = 0.018), and to 22.3 units at week 12 (p = 0.018).
Blood Pressure (SBP and DBP), LDL-C, HDL-C, TG and TC
There were no significant changes in SBP and DBP at week 4, 8, and 12 in comparison with week 0. There were also no significant changes in LDL-C, HDL-C, TG and TC between weeks 0 and 12.
AST, ALT, and urinary albumin excretion rate
There were no significant changes in AST and ALT at week 4, 8, and 12 in comparison with week 0. There was also no significant change in the albumin excretion rate between weeks 0 and 12.
Daily profile with SMBG at weeks 0 and 12
The SMBG data (10 times/day) are shown in Fig.   Fig. 2 The daily profiles of blood glucose levels measured with self-monitoring of blood glucose (10 times/day). Data are means ± SD. Asterisks denote significant differences (Wilcoxon signed rank t-test) between values at 0 week and week 12. **: p < 0.01 study (weeks 4 and 8), as shown in Table 2 . Since the dose of bolus insulin was titrated, hypoglycemic events before lunch and dinner at week 12 were significantly reduced. Even though patients used less bolus insulin in this study, we achieved an improvement in blood glucose levels after meals when we compare the results of SMBG at weeks 0 and 12 (Figure 2 ). In the SMBG record by the subjects in their ordinary daily lives, we were able to measure a significant suppression in postprandial blood glucose levels only at 1 h after dinner, since the carbohydrate intake is relatively high at dinner in Japanese T1DM patients and the effect of alphaglucosidase inhibitors would be most evident. Since combination therapy of miglitol and insulin reduced glucose fluctuations throughout the day in this study, we speculate that this therapy could slow the onset and progression of microvascular complications and cardiovascular events in T1DM patients. Kubo et al. have shown that addition of miglitol on intensive insulin therapy in T1DM patients resulted in an improvement of postprandial hyperglycemia with a reduction of insulin dosage [12] . However, they could
Discussion
The combination of insulin therapy and miglitol treatment has been previously reported to improve postprandial hyperglycemia in T1DM patients [9, 10] and to enable decreased dosages of insulin [11] , however the insulin regimen in those reports were evidently different from the standard regimen in intensive insulin therapy involving ultra-rapid acting insulin preparations, which are currently available in T1DM patients. The present study clearly shows that addition of miglitol, an alpha-glucosidase inhibitor, on intensive insulin therapy in T1DM patients has beneficial effects on improving HbA1c, GA, and 1,5-AG levels and on reducing BMI, bolus and total insulin dosage, and frequency of preprandial hypoglycemic events.
One of the objectives of the combined administration of miglitol in T1DM patients treated with insulin is to obtain target HbA1c without significant hypoglycemia and to improve postprandial hyperglycemia. Although it was not significant, the frequency of hypoglycemia after meals increased at the beginning of the bers in T1DM patients [21] . In addition, it is possible that the miglitol-induced increase of GLP-1 secretion in this study did not achieve sufficient concentrations to inhibit glucagon secretion. Another hypothesis to account for the increased glucagon response in the present study is the difference of plasma glucose levels in MTT. As shown in Figure 3A , compared to the glucose level measured at week 0, the mean glucose level at week 12 after meal ingestion was significantly suppressed. Further study is necessary to clarify the reason why glucagon was not suppressed in relation to both incretins after addition of miglitol on T1DM patients.
Since glucagon level at MTT in this study was not suppressed, we cannot demonstrate that GLP-1 elevation affected on the improvement of glycemic control in this study. GLP-1 may have contributed to the better glycemic control by mild appetite loss which was not apparent at the questionnaire test , however, the underlying mechanism in relation to GLP-1 response after addition of miglitol in this study is still unclear. And further, since miglitol suppressed the steep postprandial elevation of plasma glucose, the dose of bolus insulin could be decreased remarkably. By decreasing bolus insulin doses, a reduction of preprandial hypoglycemic events and body weight was achieved, and vice versa.
Another possible mechanism underlying the beneficial effect of combination therapy could be the modification of the responses of GIP. The BMI of the subjects significantly decreased over the course of the study, as shown in Table 2 . The reduction in body weight could be due to the decrease of the GIP level. Yamada et al. demonstrated that GIP has not only an insulinotropic role, but also physiological roles on fat accumulation into adipose tissues; they proposed a new acronym, GIP (gut-derived nutrient-intake peptide) [22] . As GIP decreased significantly in this co-administration study of miglitol, we think that body weight loss could occur by a decrease of fat accumulation into adipose tissue. Consquently, a reduction in BMI has the potential to reduce the requirements for bolus insulin doses and the frequency of hypoglycemic events.
Since the study was analyzed based on the relatively small number of patients, we also need further investigation of a large number of T1DM patients to elucidate the relationship between improved blood glucose control and the response of incretin after the addition of miglitol.
not identify the precise mechanism of the improvement of blood glucose control in relation to the response of incretin hormones. The changes of GLP-1 and GIP concentrations in healthy subjects or T2DM patients who take miglitol have been examined in several studies. Arakawa et al. and Aoki et al. studied subjects without diabetes and showed that miglitol increased the plasma GLP-1 levels after meals [13, 14] . In T2DM patients, Lee et al. demonstrated that miglitol induced an enhanced and prolonged GLP-1 release after ingesting an ordinary meal [15] , and Narita et al. demonstrated that miglitol induced prolonged and enhanced GLP-1 and reduced GIP responses after ingestion of a mixed meal by Japanese T2DM patients [16] . However, the effect of combination therapy of miglitol and insulin on secretion of incretin in T1DM patients who have been treated with intensive insulin therapy is a novel finding of this study.
This is the first report of miglitol-insulin combination therapy analyzing the modification of incretin responses in T1DM patients undergoing MTT.
In the present study, at week 12, the active GLP-1 at 120 min significantly increased, and the total GIP significantly decreased, as shown in Figure 3B and C. Our investigation of incretin hormone levels before and after MTT showed that combination therapy of miglitol and insulin in T1DM patients not only delays the absorption of carbohydrates, but also significantly decreases the secretion of GIP and increases the secretion of GLP-1. Because miglitol has the potential to decrease the absorption of carbohydrates at the upper small intestine and increase the absorption at the lower small intestine, the GIP secreted from K cells, primarily in the proximal small intestine, was decreased. In contrast, the level of GLP-1 secreted from L cells, primarily in the distal portion of the small intestine, was increased throughout MTT.
To clarify the mechanism of achieving better glycemic control in T1DM patients undergoing miglitol and intensive insulin combination therapy, we measured IRG in MTT. We expected that the secretion of glucagon might be suppressed in MTT, because both GLP-1 and GLP-1 receptor agonists suppress glucagon secretion during euglycemia in healthy subjects [17] [18] [19] [20] . Although active GLP-1 significantly increased in MTT at week 12, we could not find any significant difference in IRG between week 0 and 12. This could be due to severely impaired function of alpha cells in T1DM; although the alpha cells are still present in normal num-tion of the responses of incretins, GIP and GLP-1.
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conclusions
The present study showed that addition of miglitol on intensive insulin therapy in T1DM patients has beneficial effects on the stabilization of glycemic control and reduction of BMI, bolus and total insulin dosage, and frequency of preprandial hypoglycemic events. By combining miglitol with insulin, the fluctuation in daily profiles of blood glucose levels in T1DM could be minimized.
Furthermore, our MTT results suggest that combination therapy of miglitol and insulin in T1DM patients improves their blood glucose control via not only a delay in carbohydrate absorption but also the modificareferences
